Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a copper ring replace the pill? small study tests safety

NCT ID NCT07666997

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new type of birth control: a copper vaginal ring that women insert themselves, like NuvaRing, but without hormones. The ring is meant to prevent pregnancy using copper, similar to a copper IUD but less invasive. Eight women will wear the ring for 28 days, and researchers will check for side effects, comfort, and how well it stays in place.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
copper vaginal ring
What this could lead to
If safe and well-tolerated, this could lead to a new non-hormonal birth control option that women can insert themselves, avoiding side effects of hormonal methods and risks of IUDs.
What could go wrong
This is a very small early safety study with only 8 participants, so results may not apply to everyone. The ring may cause discomfort, irritation, or other issues that could stop development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 8 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biological female * Age \>18 * Premenopausal women * Regular, normal, cyclic menses, with a usual length of 21 to 35 days * Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol Exclusion Criteria: * Use of oral contraceptives, Copper-IUD, hormonal-IUD, another intravaginal contraceptive device, or any other method of female birth control within 3 months prior to study enrollment * Postmenopausal * Biological male * Positive urine pregnancy test at screening visit * Use of hormone therapy; injectable within the past 6 months; implantable within the past 3 months; * Presence of a vaginal/cervical/uterine anomaly or a diagnosed pathology that effects the vaginal cavity and may impair the ability to safely insert/remove a vaginal ring. * The presence of certain conditions of relevance to vaginal ring use, such as cervicitis, vaginitis or bleeding cervical erosion; lichen sclerosis, lichen planus or vaginismus; Papanicolau (PAP) grade III-V cervical smear result; prolapse of uterine cervix, cystocele and/or rectocele; severe or chronic constipation, dyspareunia or other coital problems; . * History or current diagnosis of any of the following: * gynecological cancer * fibroids * polycystic ovary syndrome * Past exposure to radiation therapy to the pelvis, or planned radiation therapy to the pelvis during the study; * Current diagnosis of a sexually transmitted disease; * Wilson's Disease; * Known allergy to metal or silicone * Had an abortion or breastfeeding within 2 months before the start of the trial; * Presence of a significant medical condition or health concern that, in the opinion of the investigator, may impact the patient's safety or the study's outcomes; * A condition that, in the opinion of the investigator, precludes the patient from being able to provide informed consent; * Inability or unwillingness to refrain from using a tampon/menstrual cup for the duration of the study. * Known inability to tolerate products/devices in the vagina (i.e., tampons, menstrual cups, vaginal rings, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Birth control are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.